Arecor Therapeutics PLC
08 October 2026
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Half year results investor presentation
Cambridge, UK, 8 October 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces that Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will be providing a live presentation of the Group's recently announced half year results for the six months to 30 June 2026 via the Investor Meet Company platform on Monday 12 October at 14:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 11 October, 09:00 BST, or at any time during the live presentation.
To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:
https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor
Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
+44 (0) 1223 426060 |
|
|
|
|
Singer Capital Markets Advisory LLP |
+44 (0) 20 7496 3000 |
|
Jen Boorer, James Fischer |
|
|
|
|
|
Vigo Consulting (Financial Communications) |
+44 (0) 20 7390 0230 |
|
|
|
|
Vida Strategic Partners (US Investor Relations) Stephanie Diaz |
+1 (415) 675-7401
|
|
Vida Strategic Partners (US Media Relations) Jennifer Arcure |
+1 (917) 603-0681 |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Arecor's research and development activity is focused on its two proprietary insulin candidates, AT278, an ultra-concentrated, ultra-rapid-acting insulin (500U/mL), and AT290, a concentrated, ultra-rapid-acting insulin (200U/mL). These insulins have been designed to enable the next generation of longer wear, miniaturised and fully closed loop automated insulin delivery (AID) systems, and have the potential to be the only insulins in development with the profile to achieve this. These next generation AID systems in combination with Arecor's insulins have the potential to reduce treatment burden and improve outcomes for people living with both type 1 and type 2 diabetes who require intensive insulin therapy (IIT).
Broadening access to next generation AID systems also represents a significant commercial opportunity. In the United States, there are approximately four million people with diabetes on IIT, who are candidates for AID. This translates to an insulin revenue market of approximately $5 billion, of which Arecor has identified the people with the highest unmet need for its insulins represent approximately $3 billion market opportunity in the US alone.
Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist. Current treatment options are mostly limited to injectable therapies, due to the low oral bioavailability of orally delivered peptides and it is this challenge that Arecor is seeking to overcome.
The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com
Arecor® and Arestat® are registered trademarks of Arecor Limited.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.